Stem Cell Therapeutics Advances CD47 Antagonist Program Into IND-Enabling … – Stockhouse
|
Stem Cell Therapeutics Advances CD47 Antagonist Program Into IND-Enabling …
Stockhouse TORONTO, ONTARIO–(Marketwired – Sept. 9, 2013) – Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), a biopharmaceutical company developing cancer stem cell– related therapeutics, today announced that it has advanced its CD47 … |
